[A23-25] Dupilumab (atopic dermatitis, 6 months to 5 years) – Benefit assessment according to §35a Social Code Book V

Last updated 03.07.2023

Project no.:

Commission awarded on 30.03.2023 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Children's and adolescents' health


Children with severe atopic dermatitis, 6 months to 5 years old, who are candidates for systemic therapy

Result of dossier assessment:
  • Children whose clinical picture is sufficiently similar to that of adults: hint of a non-quantifiable added benefit
  • Children whose clinical picture is not sufficiently similar to that of adults: added benefit not proven

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form